Jones Maris S, Torisu-Itakura Hitoe, Flaherty Devin C, Schoellhammer Hans F, Lee Jihey, Sim Myung-Shim, Faries Mark B
John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA.
Am Surg. 2016 Oct;82(10):1009-1013.
The impact on survival of a second primary melanoma (SPM) is unclear. We used our melanoma center's database to examine clinicopathologic risk factors and outcomes of stage 0 to IV cutaneous melanoma in patients with one versus two primaries. Among 12,325 patients with primary melanoma, 969 (7.86%) developed SPM. SPMs were significantly thinner than autologous primary melanomas (P = 0.01), and 451 SPM patients had better overall and melanoma-specific survival than 451 prognostically matched non-SPM patients (P < 0.0001 and 0.0001, respectively) at a median follow-up of 142.37 months. Patients with cutaneous melanoma are at high risk for development of SPM, but the development of SPM does not seem to impair survival.
第二原发性黑色素瘤（SPM）对生存的影响尚不清楚。我们利用我们黑色素瘤中心的数据库，研究了一原发性与二原发性皮肤黑色素瘤患者0至IV期的临床病理危险因素及转归。在12325例原发性黑色素瘤患者中，969例（7.86%）发生了SPM。SPM比自体原发性黑色素瘤明显更薄（P = 0.01），在中位随访142.37个月时，451例SPM患者的总生存率和黑色素瘤特异性生存率均优于451例预后匹配的非SPM患者（分别为P < 0.0001和0.0001）。皮肤黑色素瘤患者发生SPM的风险较高，但SPM的发生似乎并不影响生存。
